ABBV vs ADCT · P/E 81, rev $61.16B vs rev $70.8M
AbbVie Inc (ABBV) versus ADC Therapeutics SA (ADCT) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported ADCT revenue for 2024-12-31 was $70.8M. Net income was -$157.8M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. ADCT currently screens at market cap $141.2M.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. ADCT currently screens at market cap $141.2M.
Not investment advice. Open the ABBV and ADCT stock pages for the full models.
Not investment advice.